Venous Thrombosis targeted mutation analysis
||Factor V, prothrombin/Factor II, MTHFR
|Price / TAT:
||87 EUR / 1-2 weeks
||2-4 ml of blood with anticoagulant EDTA
300 ng DNA in TE, AE or pure sterile water at 100-250 ng/µl
The A260/A280 ratio should be 1.8-2.0. DNA sample should be run on an agarose gel as a single band, showing no degradation, alongside with a quantitative DNA marker.
Indications for genetic testing:
- Vein thrombosis before the age of 50
- Recurrent vein thrombosis in family
- Identified genetic variant for higher risk of venous thrombosis in family
For women in addition to the above named:
- Myocardial infarction in 50-year-old women who are smoking
- Vein thrombosis in the period of taking oral contraceptives
- The presence of pregnancy complications, for example multiple miscarriages, preeclampsia and stillbirth.
The annual incidence of venous thrombosis ranges from approximately 1 to 3 per 1000 people. Venous thrombosis events often occur when multiple risk factors, including genetic and environmental, are present simultaneously. Acquired risk factors of venous thrombosis are age, immobilization, surgery, trauma, malignancy, myeloproliferative disorders, obesity, pregnancy, postpartum period, hormone replacement therapy or use of oral contraceptives. Genetic risk factors are related to a 30- to 80-fold higher risk for developing a thrombotic episode.